

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
2 June 2005 (02.06.2005)

PCT

(10) International Publication Number
WO 2005/049029 A1

(51) International Patent Classification⁷: **A61K 31/495**,
31/704, A61P 35/00

(21) International Application Number:
PCT/GB2004/050025

(22) International Filing Date:
12 November 2004 (12.11.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0326486.8 14 November 2003 (14.11.2003) GB

(71) Applicant (for all designated States except US):
PHARMA MAR, S.A.U. [ES/ES]; Polígono Industrial La Mina, Avda. de los Reyes, 1, Colmenar Viejo, E-28770 Madrid (ES).

(71) Applicant (for SD only): **RUFFLES, Graham** [GB/GB];
66-68 Hills Road, Cambridge Cambridgeshire CB2 1LA (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **GIANNI, Luca** [IT/IT]; Istituto Nazionale dei Tumori, Via Venezian, 1, I-20133 Milan (IT). **D'INCALCI, Maurizio** [IT/IT]; Institute de Recherche Farmacologiche Mario Negri, Via Eritrea, 62, I-20157 Milan (IT). **DE BRAUD, Flippo** [IT/IT]; Istituto Europeo di Oncologia, Via Ripamonti, 435, I-20141 Milan (IT). **MARSONI, Silvia** [IT/IT]; South Europe New Drugs Organization, Via Visconti di Modrone, 12, I-20122 Milan (IT). **JIMENO DONAQUE,**

José María [ES/ES]; Polígono Industrial La Mina, Avda. de los Reyes, 1, Colmenar Viejo, E-28770 Madrid (ES). **LOPEZ LAZARO, Luis** [ES/ES]; Polígono Industrial La Mina, Avda. de los Reyes, 1, Colmenar Viejo, E-28770 Madrid (ES).

(74) Agent: **Marks & Clerk**; 66-68 Hills Road, Cambridge, Cambridgeshire CB2 1LA (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: COMBINATION THERAPY COMPRISING THE USE OF ET-743 AND DOXORUBICIN FOR TREATING CANCER

(57) Abstract: Methods of treating a human body for cancer are provided. In one aspect, a therapeutic amount of doxorubicin is administered in combination with ET-743 in a dose range between 0.5 and 1 mg/m². In a related aspect, an effective therapeutic amount of ET-743 is administered in combination with doxorubicin in a dose range between 40 and 80 mg/m².

WO 2005/049029 A1